K2B Therapeutics

K2B Therapeutics is developing protein-drug/siRNA conjugates with the potential for tumor-agnostic treatment of cancer. Our team believes that K2B's conjugates will revolutionize cancer therapeutics and address significant unmet need.

The foundational technology was developed at KIST (Korea Institute of Science and Technology).